<DOC>
	<DOCNO>NCT01730248</DOCNO>
	<brief_summary>The purpose phase Ib clinical trial evaluate safety combination INC424 BKM120 myelofibrosis population establish maximum tolerate dose Recommended Phase II dose combination guided Bayesian dose escalation model . INC424 show efficacy myelofibrosis ( MF ) approve US EU treatment MF . BKM120 PI3K inhibitor . Preclinical early clinical experience support inhibition PI3K/mTOR pathway MF aberrant activation pathway observe MF model may contribute pathogenesis disease .</brief_summary>
	<brief_title>A Study Find Maximum Tolerated Dose Experimental Combination Drugs INC424 BKM120 Patients With Primary Secondary Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Diagnosed PMF , PPVMF PETMF irrespective JAK2 mutation status Myelofibrosis patient require therapy must classify intermediate risk level 1 ) 1 prognostic factor define IWG ) least one criterion age Must palpable spleen least 5 cm costal margin point great splenic profusion Screening Must active symptom MF ( one symptom score least 5 two symptom score least 3 Screening ) ( per MFSSF 010 ) PLT count &gt; = 75X 10^9/L Screening Cycle 1 Day 1 ( aid transfusion Pregnant nursing woman WOCBP use highly effective method contraception Sexually active male refuse condom use Previous Treatment one following : PI3 K inhibitor AKT inhibitor ; JAK inhibitor result clinically significant toxicity per Investigator ; Patients splenic irradiation within 12 month prior Screening Patients specific mood disorder Any history bleeding diathesis Patients receive follow treatment / medication : EIAED within 2 wks . prior study treatment ; medication know prolong QT interval induce Torsades de Pointes ; treatment potent systemic systemic inhibitor systemic inducer CYP3A4 ; use drug interferes coagulation inhibits PLT function current willing candidate stem cell transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myelofibrosis ,</keyword>
	<keyword>PMF ,</keyword>
	<keyword>PPV-MF ,</keyword>
	<keyword>PET-MF ,</keyword>
	<keyword>Primary Myelofibrosis ,</keyword>
	<keyword>Post-polycythemia vera myelofibrosis ,</keyword>
	<keyword>Post-essential thrombocythemia myelofibrosis</keyword>
</DOC>